JP2008508353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508353A5 JP2008508353A5 JP2007524768A JP2007524768A JP2008508353A5 JP 2008508353 A5 JP2008508353 A5 JP 2008508353A5 JP 2007524768 A JP2007524768 A JP 2007524768A JP 2007524768 A JP2007524768 A JP 2007524768A JP 2008508353 A5 JP2008508353 A5 JP 2008508353A5
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- dihydro
- phenyl
- tetrahydro
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- -1 methoxy, hydroxy Chemical group 0.000 claims 93
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims 2
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000004747 1,1-dimethylethoxycarbonyl group Chemical group CC(C)(OC(=O)*)C 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- CZLMRJZAHXYRIX-UHFFFAOYSA-N 1,3-dioxepane Chemical compound C1CCOCOC1 CZLMRJZAHXYRIX-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- YHCUZRJTNSWYCY-UHFFFAOYSA-N 2,3,4,7-tetrahydro-1h-azepine Chemical compound C1CNCC=CC1 YHCUZRJTNSWYCY-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- BAKUAUDFCNFLBX-UHFFFAOYSA-N 4,7-dihydro-1,3-dioxepine Chemical compound C1OCC=CCO1 BAKUAUDFCNFLBX-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0401971A SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Piperidne derivatives |
| PCT/SE2005/001189 WO2006014136A1 (en) | 2004-08-02 | 2005-07-27 | Piperidine derivatives as histamine h3 receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508353A JP2008508353A (ja) | 2008-03-21 |
| JP2008508353A5 true JP2008508353A5 (enExample) | 2009-03-12 |
Family
ID=32906883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007524768A Abandoned JP2008508353A (ja) | 2004-08-02 | 2005-07-27 | ヒスタミンｈ３受容体リガンドとしてのピペリジン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080064706A1 (enExample) |
| EP (1) | EP1781613A1 (enExample) |
| JP (1) | JP2008508353A (enExample) |
| KR (1) | KR20070043998A (enExample) |
| CN (1) | CN1993325A (enExample) |
| AU (1) | AU2005267932A1 (enExample) |
| BR (1) | BRPI0514035A (enExample) |
| CA (1) | CA2576112A1 (enExample) |
| IL (1) | IL180548A0 (enExample) |
| MX (1) | MX2007001226A (enExample) |
| RU (1) | RU2007105970A (enExample) |
| SE (1) | SE0401971D0 (enExample) |
| WO (1) | WO2006014136A1 (enExample) |
| ZA (1) | ZA200700683B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089380A2 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
| JP4943837B2 (ja) | 2003-04-03 | 2012-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良インヒビター |
| ZA200703613B (en) | 2004-10-20 | 2009-05-27 | Univ California | Improved inhibitors for the soluble epoxide hydrolase |
| PL2937341T3 (pl) | 2004-12-30 | 2017-11-30 | Janssen Pharmaceutica N.V. | Pochodne fenyloamidowe kwasu 4-(benzylo)-piperazyno-1-karboksylowego oraz związki powiązane, jako modulatory hydrolazy amidu kwasu tłuszczowego (FAAH) do leczenia lęku, bólu i innych schorzeń |
| CA2606004A1 (en) | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| CN101784529A (zh) * | 2007-06-22 | 2010-07-21 | 弗·哈夫曼-拉罗切有限公司 | 作为非核苷逆转录酶抑制剂的脲和氨基甲酸酯衍生物 |
| DK2221298T3 (da) | 2007-11-13 | 2013-11-18 | Taisho Pharmaceutical Co Ltd | Phenylpyrazolderivater |
| WO2010068453A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010068452A1 (en) * | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
| WO2011069063A2 (en) | 2009-12-04 | 2011-06-09 | Sunovion Pharmaceuticals, Inc. | Multicyclic compounds and methods of use thereof |
| US9296693B2 (en) | 2010-01-29 | 2016-03-29 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| CA2801074A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| WO2012113103A1 (en) * | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| AR088256A1 (es) | 2011-10-08 | 2014-05-21 | Novartis Ag | Derivados de carbamato / urea como antagonistas del receptor h3 |
| RU2618228C2 (ru) | 2011-12-08 | 2017-05-03 | Тайсо Фармасьютикал Ко., Лтд. | Производное фенилпиррола |
| EP2799436A4 (en) | 2011-12-27 | 2015-07-01 | Taisho Pharmaceutical Co Ltd | PHENYLTRIAZOLDERIVAT |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
| TWI703130B (zh) * | 2014-03-07 | 2020-09-01 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
| CN106536518B (zh) * | 2014-05-19 | 2020-05-12 | 勃林格殷格翰动物保健美国公司 | 驱蠕虫化合物 |
| EP3383853B1 (en) | 2015-12-01 | 2020-11-04 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease |
| KR102640774B1 (ko) | 2016-03-22 | 2024-02-26 | 헬신 헬쓰케어 에스.에이. | 벤젠술포닐-비대칭 우레아 및 그의 의학적 용도 |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| CA3032141A1 (en) | 2016-07-29 | 2018-02-01 | Vadim ALEXANDROV | Compounds and compositions and uses thereof |
| AU2017301769B2 (en) | 2016-07-29 | 2022-07-28 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
| HUE057710T2 (hu) | 2017-01-23 | 2022-05-28 | Cadent Therapeutics Inc | Káliumcsatorna modulátorok |
| WO2018151861A1 (en) | 2017-02-16 | 2018-08-23 | Sunovion Pharamaceuticials Inc. | Methods of treating schizophrenia |
| EA202090414A1 (ru) | 2017-08-02 | 2020-05-28 | Суновион Фармасьютикалз Инк. | Соединения и их применение |
| CA3091292A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| CN120097995A (zh) | 2018-05-21 | 2025-06-06 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| JP2022508945A (ja) | 2018-10-22 | 2022-01-19 | カデント セラピューティクス，インコーポレーテッド | カリウムチャネルモジュレーターの結晶形態 |
| CN111349609A (zh) * | 2018-12-21 | 2020-06-30 | 泰州医药城国科化物生物医药科技有限公司 | 一种无标记组胺受体h3的细胞筛选模型 |
| EP3938045A1 (en) | 2019-03-14 | 2022-01-19 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
| EP3969444A4 (en) * | 2019-05-13 | 2023-10-18 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES AND DISORDERS |
| SI4003532T1 (sl) | 2019-07-24 | 2025-02-28 | Constellation Pharmaceuticals, Inc. | Kristalinične oblike 7-kloro-2-(4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-N-((6-metil-4-(metilthio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamida |
| ES2819309B2 (es) * | 2019-10-14 | 2021-11-17 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas |
| MX2022012833A (es) | 2020-04-14 | 2022-11-07 | Sunovion Pharmaceuticals Inc | (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos. |
| CN113549006B (zh) * | 2020-04-26 | 2023-07-21 | 江苏恩华药业股份有限公司 | 一种酰胺衍生物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0343307A1 (en) * | 1988-05-26 | 1989-11-29 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. | 4-Piperidinealkanamine derivatives |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE60234616D1 (de) * | 2001-09-14 | 2010-01-14 | High Point Pharmaceuticals Llc | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren |
| US6673829B2 (en) * | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
| US7064135B2 (en) * | 2001-10-12 | 2006-06-20 | Novo Nordisk Inc. | Substituted piperidines |
| WO2004037800A1 (en) * | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| US7332508B2 (en) * | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| CN1902177A (zh) * | 2003-09-22 | 2007-01-24 | 万有制药株式会社 | 新哌啶衍生物 |
-
2004
- 2004-08-02 SE SE0401971A patent/SE0401971D0/xx unknown
-
2005
- 2005-07-27 JP JP2007524768A patent/JP2008508353A/ja not_active Abandoned
- 2005-07-27 RU RU2007105970/04A patent/RU2007105970A/ru not_active Application Discontinuation
- 2005-07-27 US US11/572,967 patent/US20080064706A1/en not_active Abandoned
- 2005-07-27 AU AU2005267932A patent/AU2005267932A1/en not_active Abandoned
- 2005-07-27 MX MX2007001226A patent/MX2007001226A/es not_active Application Discontinuation
- 2005-07-27 KR KR1020077002643A patent/KR20070043998A/ko not_active Withdrawn
- 2005-07-27 CA CA002576112A patent/CA2576112A1/en not_active Abandoned
- 2005-07-27 CN CNA2005800262732A patent/CN1993325A/zh active Pending
- 2005-07-27 EP EP05761797A patent/EP1781613A1/en not_active Withdrawn
- 2005-07-27 WO PCT/SE2005/001189 patent/WO2006014136A1/en not_active Ceased
- 2005-07-27 BR BRPI0514035-8A patent/BRPI0514035A/pt not_active Application Discontinuation
-
2007
- 2007-01-04 IL IL180548A patent/IL180548A0/en unknown
- 2007-01-24 ZA ZA200700683A patent/ZA200700683B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508353A5 (enExample) | ||
| CN100418951C (zh) | 环胺衍生物及其作为药物的用途 | |
| JP4753403B2 (ja) | インテグリンのそのレセプターへの結合を阻害する化合物 | |
| ES2291464T3 (es) | Derivados de n-(arilsulfonil)beta-aminoacidos que comprenden un grupo aminoetilo sustituido, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| RU2007105970A (ru) | Пиперидиновые производные в качестве лигандов гистаминового из рецептора | |
| ES2240339T3 (es) | Derivados de oxibenzamidas en calidad de inhibidores de factor xa. | |
| KR100927563B1 (ko) | 방향족 화합물 | |
| JP5188814B2 (ja) | 有機化合物 | |
| JP2008508352A5 (enExample) | ||
| JP2004520435A (ja) | 新規非イミダゾール化合物 | |
| RU2003127723A (ru) | Ацилированные 6, 7, 8, 9 - тетрагидо - 5h - бензоциклогептениламины и их применение в качестве фармацевтических препаратов | |
| US20070249618A1 (en) | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | |
| SK16152002A3 (sk) | Farmacueticky účinné piperidínové deriváty, najmä ako modulátory aktivity chemokínového receptora | |
| PT2207773E (pt) | Composto heterocíclico e composição farmacêutica que contém o mencionado composto | |
| JPWO2006057270A1 (ja) | 含窒素３環化合物 | |
| JPWO2004101514A1 (ja) | シアノフルオロピロリジン誘導体 | |
| CN100422151C (zh) | 二芳基亚甲基哌啶衍生物、其制备及其用途 | |
| ES2286474T3 (es) | Derivados de 4-(finilpiperazinilmetil) benzamida y su uso para el tratamiento de dolor o transtornos gastrointestinales. | |
| KR20080013933A (ko) | 레닌 억제제로서의 치환된 피페리딘 | |
| CN102548985A (zh) | 取代羰基化合物 | |
| SK286687B6 (sk) | Sulfónamidy, spôsob ich výroby, medziprodukty, liečivo a farmaceutická kompozícia s ich obsahom | |
| SK13912003A3 (sk) | 4-(Fenyl(piperidin-4-yl)amino)benzamidové deriváty a ich požitie na liečbu bolesti, anxiety alebo gastrointestinálnych porúch | |
| ES2285179T3 (es) | Derivados de fenil-piperidin-4-ilidene-metil-benzamida para el tratamiento de dolor o trastornos gastrointestinales. | |
| JPWO2005030722A1 (ja) | Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体 | |
| CN115667227B (zh) | 基质金属蛋白酶(mmp)抑制剂及其使用方法 |